| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
First Department of Internal Medicine (A.N.-O., M.N., Y.O., H.S.), Department of Clinical Laboratory Medicine (Y.I.), Nagoya University School of Medicine, Nagoya 466-8550; Department of Cell Regulation, Saitama University (K.I.), Saitama 338-0825, Japan
Address all correspondence and requests for reprints to: Yasumasa Iwasaki, M.D., Department of Clinical Laboratory Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: iwasakiy{at}mb.infoweb.ne.jp
Although insulin-like growth factor-I (IGF-I) is shown to have a
suppressive effect on GH gene expression at the pituitary level, its
molecular mechanism has not yet been clarified. To study the issue, we
established a new in vitro system using MtT/S, a
recently established rat somatotroph tumor cell line that retains the
basic characteristics of somatotroph function. Plasmids containing the
GH 5' promoter (
1.75 kb or shorter)-luciferase fusion gene were
transfected stably or transiently into the cells, and the effect of
IGF-I on the GH promoter activity was estimated by a luciferase assay.
The results showed that IGF-I inhibited GH promotor activity (more than
50% suppression) in a time- and dose-related manner. IGF-I also
inhibited GH secretion. A study using deletion mutants of the GH
promoter revealed that the negative effect was maintained in the
shortest construct (-80 to +6), suggesting that IGF-I-related factor
is acting at the region very close to the minimal promoter.
Interestingly, the negative effect was completely eliminated by a
PI3 kinase inhibitor wortmannin (1 µM),
whereas a MAP kinase inhibitor PD98059 (20 µM) or S6
kinase inhibitor rapamycin (10 nM) did not influence the
effect. Our results suggest that IGF-I suppresses GH gene expression at
the transcriptional level and that the PI3 kinase-mediated
signaling pathway plays a major role in the negative effect of IGF-I.
We believe that our system using MtT/S cells is an excellent
experimental model system for studying the cellular and molecular
mechanisms of the transcriptional regulation of GH in
vitro.
This article has been cited by other articles:
![]() |
R. M Luque, M. D Gahete, R. J Valentine, and R. D Kineman Examination of the direct effects of metabolic factors on somatotrope function in a non-human primate model, Papio anubis. J. Mol. Endocrinol., August 1, 2006; 37(1): 25 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Huo, G. Fu, X. Wang, W. K. W. Ko, and A. O. L. Wong Modulation of Calmodulin Gene Expression as a Novel Mechanism for Growth Hormone Feedback Control by Insulin-like Growth Factor in Grass Carp Pituitary Cells Endocrinology, September 1, 2005; 146(9): 3821 - 3835. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Voss, M. P. Flynn, and D. L. Hurley IGF-I Causes an Ultrasensitive Reduction in GH mRNA Levels via an Extracellular Mechanism Involving IGF Binding Proteins Mol. Endocrinol., September 1, 2001; 15(9): 1549 - 1558. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fruchtman, L. Jackson, and R. Borski Insulin-Like Growth Factor I Disparately Regulates Prolactin and Growth Hormone Synthesis and Secretion: Studies Using the Teleost Pituitary Model Endocrinology, August 1, 2000; 141(8): 2886 - 2894. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |